skip to main content



Catalogue No.


Cell Line Name


Cell Line Description

ESO51 was established from a primary adenocarcinoma of the distal oesophagus with the presence of Barrett's transformed mucosa in a 74 year-old Caucasian male in 2000. ESO51 was found to be tumourigenic in female NMRI nude mice or NOD-SCID mice. The Y chromosome could not be detected in this cell line by short tandem repeat (STR)-PCR analysis when tested at ECACC. It is a known phenomenon that due to the increased genetic instability of cancer cell lines the Y chromosome can be rearranged or lost resulting in lack of detection. The cell line is identical to the source provided by the depositor based on the STR-PCR analysis.Cultures derived from ECACC stocks of this cell line have been whole genome sequenced (Contino et al 2016) confirming the presence of many of the known mutations that drive oesophageal cancer



Not specified


P53 mutation c.524G>A

Tissue of Origin


DNA profile (STR Profile)

Amelogenin: X
CSF1PO: 10
D5S818: 11
D7S820: 8.2
D13S317: 11
D16S539: 13
TH01: 9
vWA: 14,15


Not specified



Culture Conditions

Cell Type


Subculture Routine

It is recommended that the DMSO should be removed by centrifugation and the cells seeded at 3x10⁵ on resuscitation. To subculture the cells, add an equal volume of fresh medium to the culture every other day. Culture has a maximum saturation density of approximately 4x10⁵ cells/ml.

Recommended growth conditions 5% CO2; 37°C.

Culture Medium

RPMI-1640 + 2mM Glutamine + 10% Foetal Bovine Serum (FBS)

Growth Mode


Additional Info


Dr W.N.M. Dinjens, Department of Pathology, Josephine Nefkens Institute, Erasmus MC, University Medical Centre, Rotterdam PO Box 2040, 3000CA Rotterdam. Originator: Dr P Chaves Department of Pathology and Cytology, Portuguese Institute of Oncology, Lisbon, Portugal.

Country of Origin


Hazard Group (ACDP)

Hazard Group (ACDP) 2



Boonstra JJ, van Marion R, Beer DG, Lin L, Chaves P, Ribeiro C, Pereira AD, Roque L, Darnton SJ, Altorki NK, Schrump DS, Klimstra DS, Tang LH, Eshleman JR, Alvarez H, Shimada Y, van Dekken H, Tilanus HW, Dinjens WN. 2010 Verification and unmasking of widely used human esophageal adenocarcinoma cell lines. J Natl Cancer Inst. 102(4):271-4.PMID: 20075370.Whole-genome sequencing of nine esophageal adenocarcinoma cell lines


Chaves P, Dias Pereira A 2010 The biological meaning of intestinal metaplasia of the gastroesophageal junction. Int J Surg Pathol. 18(3 Suppl):43S-47S PMID: 20484260.

Available Formats

  • Frozen
  • DNA-5µg (100ng/µl)

If use of this culture results in a scientific publication, it should be cited in the publication as: ESO51 (ECACC 11012010).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country. ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.